QCOR, KERX Could Break Through Technical Barriers On Improving Fundamentals
Long Ideas - For most mutual funds, tax-loss selling must be done by the end of Monday. As a result, pressure could come off names that have had … Continue Reading
Read nowSearch Results for keryx
PropThink’s Weekly Wrap-Up
Recap - A patent extension for Folotyn added five years to the drug’s market exclusivity and elicited a rally in Spectrum (SPPI) on Monday, but the news … Continue Reading
Read nowA Fresh Look At KERX; High Odds For Zerenex Phase III Success
Long Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story … Continue Reading
Read nowAeterna Zentaris Up on Rating, Value Drivers into Next Year
Long Ideas - Shares of Aeterna Zentaris (NASDAQ:AEZS) are strong Thursday morning after a Buy initiation from Roth Capital with a $1.75 price target, more than double its … Continue Reading
Read now